Mechanism of Ocrelizumab in B-Cell Depletion

Ocrelizumab targets CD20-positive B cells

Ocrelizumab binds to CD20 on B cells and drives their depletion primarily through antibody-dependent cellular cytotoxicity mediated by monocytes via Fcγ receptor pathways, achieving rapid and sustained reduction of circulating B cells while also depleting CD20-positive T-cell subsets.

Abstract

Ocrelizumab is a humanized anti-CD20 monoclonal antibody that targets the same CD20 epitope as rituximab but achieves B-cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) rather than complement-dependent cytotoxicity (CDC). The antibody was engineered with amino acid modifications to enhance binding to Fcγ receptor IIIa, resulting in two- to five-fold greater ADCC activity compared to rituximab. Monocytes serve as the dominant effector cells mediating B-cell depletion through FcγRI and FcγRIII-dependent pathways, achieving rapid onset within hours and near-complete depletion (>95%) of circulating B cells by week 2. However, depletion efficiency varies across anatomical compartments, with secondary lymphoid organs retaining resistant B-cell subpopulations and bone marrow showing the weakest reduction. Ocrelizumab also co-depletes CD20-positive T-cell subsets and novel dual-expressor lymphocytes expressing both T-cell and B-cell receptors.

B-cell recovery begins in bone marrow and spleen before appearing in blood, with median time to repletion of 72 weeks. The phenotype of reconstituting B cells varies by immunological context: in settings with ongoing antigen stimulation, recovery is characterized by expansion of differentiated, myelin-reactive B cells, whereas absence of stimulation favors naive B-cell reconstitution. Treatment induces secondary immunological changes including increased BAFF levels and decreased sTACI, which may enhance regulatory plasma cell development and contribute to therapeutic efficacy. The ADCC-predominant mechanism provides more sustained depletion than CDC-predominant antibodies while potentially offering better tolerability.

Methods

We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Data extraction

We asked a large language model to extract each data column below from each paper.

• CD20 Targeting: Extract details about how ocrelizumab targets CD20-positive B cells, including:
  • CD20 epitope specificity and binding characteristics
  • Binding affinity
  • Structure features affecting CD20 binding
  • Comparison of binding characteristics to other anti-CD20 antibodies
  • Dose-response relationships for CD20 binding
• Cytotoxic Mechanisms: Extract all mechanisms by which ocrelizumab induces B-cell death after CD20 binding, including:
  • CDC activity and potency
  • ADCC activity and potency
  • Direct apoptosis induction
  • Other cytotoxic pathways
  • Quantitative comparisons of mechanism potency
  • Time course of cytotoxicity for each mechanism
  • Genetic or phenotypic factors affecting cytotoxic efficacy
• Depletion Patterns: Extract detailed patterns of B-cell depletion caused by ocrelizumab, including:
  • B-cell subpopulations targeted
  • B-cell populations resistant to depletion
  • Anatomical compartments affected
  • Degree of depletion in each compartment
  • Co-depletion of CD20+ T cells or other immune cells
  • Factors influencing depletion efficiency
• Depletion Kinetics: Extract timing and kinetics of B-cell depletion and recovery with ocrelizumab, including:
  • Time to initial B-cell depletion
  • Duration of maximal depletion
  • Recovery timeline for different B-cell populations
  • Recovery timeline for different anatomical compartments
  • Sequence of B-cell reconstitution
  • Phenotype of reconstituting B cells
• Molecular Determinants: Extract molecular and structural features of ocrelizumab that influence its mechanism of action, including:
  • Antibody type
  • Heavy and light chain sequences
  • Fc region modifications or glycoengineering
  • Pharmacokinetic properties affecting mechanism
  • Dosing regimen and how it relates to mechanism optimization
  • Route of administration and mechanistic implications
• Comparative Mechanisms: Extract direct comparisons of ocrelizumab’s mechanism to other anti-CD20 antibodies, including:
  • Head-to-head mechanistic comparisons
  • Relative potency differences in CDC vs ADCC mechanisms
  • Differences in B-cell depletion patterns between antibodies
  • Differences in depletion kinetics between antibodies
  • Unique mechanistic features of ocrelizumab vs competitors

Results

Characteristics of Included Studies

Mechanisms of CD20 Targeting and B-cell Depletion

CD20 Binding Characteristics

Ocrelizumab is a humanized anti-CD20 monoclonal antibody that binds to the same epitope on the large extracellular loop of CD20 as rituximab. The antibody is classified as a type I anti-CD20 agent capable of crosslinking CD20 tetramers. Enhanced binding to low-affinity variants of Fcγ receptor IIIa distinguishes ocrelizumab from rituximab, contributing to its enhanced effector function.

Cytotoxic Mechanisms

Ocrelizumab depletes B cells through multiple cytotoxic pathways, with ADCC as the primary mechanism. The antibody exhibits two- to five-fold greater ADCC activity compared to rituximab, while demonstrating three- to five-fold lower CDC activity. Studies in mouse models demonstrate that B-cell depletion is completely dependent on effector cell Fc receptor expression.

Patterns of B-cell Depletion

B-cell Subpopulations

Ocrelizumab targets CD20-positive B cells, resulting in significant reductions across multiple B-cell subsets including naive B cells, memory B cells, and transitional B cells. Plasma cells, which lack CD20 expression, remain resistant to depletion.

Anatomical Compartments

B-cell depletion occurs across multiple anatomical compartments but with varying efficiency. In blood, depletion is nearly complete, whereas B cells in lymphatic organs and the CNS are not depleted to the same extent.

Kinetics of Depletion and Recovery

Depletion Timeline

The onset of B-cell depletion is rapid, occurring within 1 hour in mouse models, with CD19+ cell counts in humans almost completely depleted by week 2 after the first dose.

Recovery Patterns

In humans, B-cell levels increase to baseline or the lower limit of normal in 90% of patients within 2.5 years after the last infusion, with a median time to repletion of 72 weeks.

Comparative Analysis with Other Anti-CD20 Antibodies

Mechanistic Distinctions

Ocrelizumab exhibits distinct mechanistic properties compared to other anti-CD20 antibodies. While all anti-CD20 agents induce both ADCC and CDC, their relative reliance on these pathways differs substantially.

Secondary Effects on Immune Regulation

BAFF-APRIL System Modulation

Ocrelizumab treatment induces profound changes in the B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) system.